GlassScriptPhysician profile
Ronequa Evans
NPI 1982205423
$2,056.57
in general payments reported to CMS, 2019-2025
13 companies · $825 in 2025
The $825 reported for 2025 was more than what 84% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $204 · 2023: $278 · 2024: $750 · 2025: $825.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,853.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,852.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $494.03 | 2022-2025 | Lokelma, Farxiga |
| Novartis Pharmaceuticals Corporation | $371.31 | 2023-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $295.27 | 2022-2025 | |
| Ardelyx, INC. | $177.23 | 2024-2025 | Xphozah 30 Mg, Ibsrela |
| Otsuka America Pharmaceutical, INC. | $149.24 | 2022-2025 | Jynarque |
| Mallinckrodt Hospital Products INC. | $143.61 | 2024-2025 | Terlivaz |
| Aurinia Pharma U.S., INC. | $138.98 | 2024-2025 | Lupkynis |
| Travere Therapeutics, INC. | $125.00 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $54.81 | 2023-2024 | Jardiance |
| Calliditas Therapeutics US INC. | $42.71 | 2024 | |
| Genentech, INC. | $25.18 | 2025 | |
| Amgen INC. | $19.72 | 2022 | |
| Nxstage Medical, INC. | $19.48 | 2025 | Crit-Line |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ronequa Evans listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.